Form 4: Axogen Director Sells Shares Under 10b5-1 Plan

Axogen Director Paul Thomas sold 21,399 shares of common stock for a weighted average price of $29.614 per share on December 9, 2025, pursuant to a pre-arranged Rule 10b5-1 plan.

Summary

• Paul Thomas, a Director of Axogen, Inc. (AXGN), reported a sale of common stock.
• The transaction involved the disposition of 21,399 shares of Axogen common stock.
• The shares were sold on December 9, 2025, at a weighted average price of $29.614 per share.
• The sale price ranged from $29.56 to $29.70 per share across multiple transactions.
• Following this transaction, Paul Thomas beneficially owns 13,528 shares of Axogen common stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. While an insider sale reduces ownership, the explicit mention of a Rule 10b5-1 plan indicates a pre-arranged, structured transaction for personal financial planning, rather than a reaction to new, non-public information. This mitigates potential negative interpretations.

Negatives

• The sale by a director reduces the total insider ownership in the company.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape. Insider sales under 10b5-1 plans are common across industries for personal financial planning.

Stakeholder Impact

• Shareholders: May observe a reduction in insider ownership, but the 10b5-1 plan context suggests it's not a signal of diminished confidence in the company's future.

Key Dates

Recommendation

The sale of shares by Director Paul Thomas was conducted under a pre-arranged Rule 10b5-1 plan, indicating a structured transaction rather than a reaction to new material non-public information. This typically reduces the negative signal often associated with insider selling, suggesting the transaction is for personal financial planning rather than a lack of confidence in Axogen's future prospects. Therefore, a 'hold' recommendation is appropriate as this event does not fundamentally alter the investment thesis.

Keywords

Axogen, AXGN, insider trading, Form 4, stock sale, director, Paul Thomas, 10b5-1 plan